Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.
Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
Health NGO, Right to Care, highlights the urgent need for circumcision among boys aged 15 and older in KwaZulu-Natal to ...
Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...
Winnie Byanyima, from UNAIDS: ‘Lenacapavir is more effective than condoms or PrEP in prevention’
The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...
Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...
HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...
“With low uptake of PrEP among the communities most impacted by HIV, this insurance coverage requirement with zero ...
GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback